Electromed (ELMD) Resumen de Acciones
Electromed, Inc. desarrolla, fabrica, comercializa y vende terapia de desobstrucción de las vías respiratorias y productos relacionados que aplican la terapia de oscilación de alta frecuencia de la pared torácica (HFCWO) en el cuidado pulmonar de pacientes en Estados Unidos e internacionalmente. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 1/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 6/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
ELMD Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Electromed, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$45.43 |
| Máximo en las últimas 52 semanas | US$45.49 |
| Mínimo de 52 semanas | US$17.73 |
| Beta | 0.50 |
| Cambio en 1 mes | 20.54% |
| Variación en 3 meses | 91.04% |
| Cambio de 1 año | 125.80% |
| Variación en 3 años | 325.37% |
| Variación en 5 años | 284.67% |
| Variación desde la OPV | 1,041.46% |
Noticias y actualizaciones recientes
ELMD: Stock Will Seek Upside From Expanding Bronchiectasis Market Opportunity
Analysts have raised the fair value estimate for Electromed to $45 from $38, citing recent record Q3 results with 18.4% revenue growth, strong operating leverage, and expectations for continued double-digit expansion in a large, underpenetrated bronchiectasis market. What’s in the News for Electromed Analysts revised Electromed’s fair value estimate to $45 from $38, reflecting updated views on the company’s fundamentals.
ELMD: Bronchiectasis Exposure And Margin Execution Will Support Future Upside
Analysts have nudged their price target on Electromed stock higher to $40 from $38, citing record Q3 results with 18.4% revenue growth, strong operating leverage, and confidence in continued double-digit expansion supported by broader adoption, payer coverage, and an underpenetrated bronchiectasis market. What's in the News Analysts raised their price target on Electromed stock to $40 from $38, citing record Q3 results and 18.4% revenue growth.Recent updates
ELMD: Stock Will Seek Upside From Expanding Bronchiectasis Market Opportunity
Analysts have raised the fair value estimate for Electromed to $45 from $38, citing recent record Q3 results with 18.4% revenue growth, strong operating leverage, and expectations for continued double-digit expansion in a large, underpenetrated bronchiectasis market. What’s in the News for Electromed Analysts revised Electromed’s fair value estimate to $45 from $38, reflecting updated views on the company’s fundamentals.ELMD: Bronchiectasis Exposure And Margin Execution Will Support Future Upside
Analysts have nudged their price target on Electromed stock higher to $40 from $38, citing record Q3 results with 18.4% revenue growth, strong operating leverage, and confidence in continued double-digit expansion supported by broader adoption, payer coverage, and an underpenetrated bronchiectasis market. What's in the News Analysts raised their price target on Electromed stock to $40 from $38, citing record Q3 results and 18.4% revenue growth.
ELMD: Refined Discount Rate And P/E Assumptions Will Drive Future Upside
Analysts raised their price target on Electromed by $2, reflecting updated assumptions about the discount rate, profit margin, revenue growth, and future P/E that support a slightly higher valuation framework. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rate and future P/E that leave room for upside if execution stays on track.ELMD: Refreshed Discount Rate And P/E Assumptions Will Support Future Upside
Analysts have raised their price target on Electromed by $2, citing updated assumptions about discount rates, revenue growth, profit margins and future P/E that support a slightly higher fair value estimate. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rates and future P/E, which together suggest more support for the current valuation than before.ELMD: Share Repurchases And Margin Execution Will Support Future Upside
Analysts have raised their price target on Electromed by $2 to reflect updated assumptions around revenue growth, profit margin and long-term P/E expectations. Analyst Commentary Recent research points to a more cautious tone around Electromed, even alongside the higher price target.ELMD: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have increased their price target on Electromed by $2 to $36, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as key factors behind the change. Analyst Commentary While the new US$36 price target reflects updated valuation work, some bearish analysts are still flagging risk factors that they believe limit upside for Electromed at current levels.ELMD: Share Repurchases Will Support Future Upside In Undervalued Shares
Analysts have nudged their price target on Electromed up by $1 to $37, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E after the latest Street research. Analyst Commentary Recent Street research has focused on how Electromed's fundamentals line up with the revised fair value assumptions and the updated $37 target.ELMD: Completed Share Buyback Will Support Future Upside In Undervalued Shares
Analysts have adjusted their price target on Electromed to reflect a fair value of $36.00, citing only minor tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E. Their overall valuation view remains largely unchanged.ELMD: Share Buyback And Higher Margin Outlook Will Support Future Upside
Analysts have kept their price target for Electromed steady at US$34.00, reflecting updated views on slightly higher projected revenue growth and profit margins, along with a marginally adjusted discount rate and future P/E assumption. What's in the News Completed the repurchase of 40,848 shares, representing 0.49% of the company, for US$1 million under the share buyback announced on September 9, 2025 (Key Developments).ELMD: Higher Margin Outlook And Share Buyback Will Support Upside Potential
Analysts have raised their fair value estimate for Electromed from US$29 to US$34, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Between September 9, 2025 and September 30, 2025, Electromed repurchased 40,848 shares for US$1 million, representing 0.49% of shares.ELMD: Share Repurchase Program Will Support Future Upside In Undervalued Shares
Analysts have nudged their price target for Electromed slightly higher to approximately $36.00 per share, citing modest improvements in discount rate assumptions and forward valuation metrics while largely reaffirming their prior outlook. What's in the News Completed a share repurchase tranche totaling 40,848 shares, or about 0.49 percent of outstanding shares, for approximately $1 million under the buyback program announced September 9, 2025 (company filing) Valuation Changes Fair Value Estimate reaffirmed at approximately $36.00 per share, reflecting no material change in intrinsic value assumptions.ELMD: Share Repurchase Plan And Expanding Outlook Will Lift Share Price
Analysts have raised their price target for Electromed from $35.25 to $36.00. They cite an improved outlook for future revenue growth, despite a slightly higher discount rate and marginally lower profit margin projections.ELMD: Double-Digit Revenue Gains And Buybacks Will Drive Shares Higher
Electromed's analyst fair value target increased slightly from $35.00 to $35.25, as analysts cite consistent double-digit revenue growth forecasts and improving operational efficiency in recent reports. Analyst Commentary Bullish Takeaways Bullish analysts highlight Electromed's consistent double-digit revenue growth forecasts and note that ongoing top-line expansion is expected in the coming years.
The Triple Down On Bronchiectasis Campaign Will Expand SmartVest Clearway's Market Reach
Diversifying beyond homecare and investing in sales efforts may drive revenue growth and improve earnings through expanded market channels and effective sales execution.Rentabilidad de los accionistas
| ELMD | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 7.6% | 2.2% | 1.6% |
| 1Y | 125.8% | -19.0% | 18.6% |
Rentabilidad vs. Industria: ELMD superó a la industria US Medical Equipment, que obtuvo un rendimiento del -19% el año pasado.
Rentabilidad vs. Mercado: ELMD superó al mercado US, que obtuvo un rendimiento del 18.6% el año pasado.
Volatilidad de los precios
| ELMD volatility | |
|---|---|
| ELMD Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: ELMD no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ELMD (9%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1992 | 179 | Jim Cunniff | smartvest.com |
Electromed, Inc. desarrolla, fabrica, comercializa y vende terapias de desobstrucción de las vías respiratorias y productos relacionados que aplican la terapia de oscilación de alta frecuencia de la pared torácica (HFCWO) en el cuidado pulmonar de pacientes en Estados Unidos e internacionalmente. La empresa ofrece el sistema de desobstrucción de las vías respiratorias SmartVest para pacientes con funciones pulmonares comprometidas, como bronquiectasias y fibrosis quística, así como afecciones neuromusculares, como parálisis cerebral, distrofias musculares, esclerosis lateral amiotrófica y complicaciones posquirúrgicas; SmartVest SQL System; SmartVest Clearway System, que consta de una prenda terapéutica inflable, un generador de impulsos de aire programable y una manguera única patentada que envía impulsos de aire del generador a la prenda para crear una presión oscilatoria en la pared torácica; y SmartVest Connect, una tecnología inalámbrica que permite la conexión de datos entre médicos y pacientes para hacer un seguimiento del rendimiento de la terapia y colaborar en las decisiones de tratamiento. También ofrece productos SmartVest y SmartVest Wrap de uso en un solo paciente para profesionales sanitarios en el ámbito de los cuidados intensivos.
Resumen de fundamentos de Electromed, Inc.
| Estadísticas fundamentales de ELMD | |
|---|---|
| Capitalización bursátil | US$376.16m |
| Beneficios(TTM) | US$10.10m |
| Ingresos (TTM) | US$71.75m |
¿Está ELMD sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ELMD | |
|---|---|
| Ingresos | US$71.75m |
| Coste de los ingresos | US$15.47m |
| Beneficio bruto | US$56.28m |
| Otros gastos | US$46.18m |
| Beneficios | US$10.10m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 1.22 |
| Margen bruto | 78.44% |
| Margen de beneficio neto | 14.08% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ELMD a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/06 08:30 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/06/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Electromed, Inc. está cubierta por 5 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |
| Ilya Zubkov | Freedom Broker |